Repositioning Candidate Details
| Candidate ID: | R1182 |
| Source ID: | DB08899 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Enzalutamide |
| Synonyms: | Enzalutamide |
| Molecular Formula: | C21H16F4N4O2S |
| SMILES: | CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F |
| Structure: |
|
| DrugBank Description: | Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012. |
| CAS Number: | 915087-33-1 |
| Molecular Weight: | 464.436 |
| DrugBank Indication: | Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. |
| DrugBank Pharmacology: | Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52. |
| DrugBank MoA: | Enzalutamide is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume. |
| Targets: | Androgen receptor inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
